GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViewRay Inc (OTCPK:VRAYQ) » Definitions » Net Current Asset Value

VRAYQ (ViewRay) Net Current Asset Value : $0.09 (As of Mar. 2023)


View and export this data going back to 2014. Start your Free Trial

What is ViewRay Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

ViewRay's net current asset value per share for the quarter that ended in Mar. 2023 was $0.09.

The historical rank and industry rank for ViewRay's Net Current Asset Value or its related term are showing as below:

VRAYQ's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 4.94
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

ViewRay Net Current Asset Value Historical Data

The historical data trend for ViewRay's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViewRay Net Current Asset Value Chart

ViewRay Annual Data
Trend Nov13 Nov14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.56 1.21 0.63 0.73 0.22

ViewRay Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.45 0.36 0.22 0.09

Competitive Comparison of ViewRay's Net Current Asset Value

For the Medical Devices subindustry, ViewRay's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViewRay's Price-to-Net-Current-Asset-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ViewRay's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where ViewRay's Price-to-Net-Current-Asset-Value falls into.


;
;

ViewRay Net Current Asset Value Calculation

ViewRay's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2022 is calculated as

Net Current Asset Value Per Share(A: Dec. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(228.354-189.155-0-0)/181.587
=0.22

ViewRay's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2023 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(193.567-177.902-0-0)/183.384
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ViewRay  (OTCPK:VRAYQ) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


ViewRay Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of ViewRay's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


ViewRay Business Description

Traded in Other Exchanges
N/A
Address
1099 18th Street, Suite 3000, Denver, CO, USA, 80202
ViewRay Inc is a radiation therapy and imaging technology company. It designs, manufactures, and markets radiation therapy systems that provide real-time imaging during radiation treatment. Its product portfolio encompasses The MRIdian linac system, The MRIdian system, the Monte Carlo treatment planning system, etc. The company holds the license for its combination of MRI and radiation therapy technologies. Geographically, it derives a majority of its revenue from the United States.
Executives
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
B Kristine Johnson director 366 FERNDALE RD S, WAYZATA MN 55391
Sanket Shah officer: SVP, General Counsel C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Farhad Fred Ebrahimi 10 percent owner 191 UNIVERSITY BLVD., #246, DENVER CO 80206
Caley Castelein director THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Paul Jr Ziegler officer: Chief Commercial Officer C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Scott William Drake director, officer: President and CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Adam Andrew Podbelski officer: SVP, Customer Services C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Jacob Edward Signoriello officer: Chief Financial Officer C/O VIEWRAY, INC., 1099 18TH STREET, SUITE 3000, DENVER CO 80202
James F. Dempsey director, officer: Chief Scientific Officer C/O VIEWRAY INCORPORATED, 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Burke William P. Mr. officer: Chief Financial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Susan C Schnabel director C/O CREDIT SUISSE FIRST BOSTON, 11 MADISON AVE, NEW YORK NY 10010
Brian K Roberts director DIGITAS INC.,, 800 BOYLSTON STREET, BOSTON MA 02199
Zachary William Stassen officer: Chief Financial Officer C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Daniel Jeffrey Moore director 100 CYBERONICS BVLD, HOUSTON TX 77058

ViewRay Headlines

From GuruFocus

Q4 2018 ViewRay Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

ViewRay Inc Clinical Data Update Call Transcript

By GuruFocus Research 02-15-2024

Q3 2022 ViewRay Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

ViewRay Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-15-2024

Q1 2022 ViewRay Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

ViewRay Inc Investor Day Transcript

By GuruFocus Research 02-15-2024

Q1 2021 ViewRay Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2019 ViewRay Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024